Related references
Note: Only part of the references are listed.Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts).
Michael Lattanzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives
Giorgio Patelli et al.
CANCER TREATMENT REVIEWS (2022)
A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.
Huayan Xu et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials.
Xinan Sheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer
Dong Chen et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Xinan Sheng et al.
CLINICAL CANCER RESEARCH (2021)
HER2-targeted therapies - a role beyond breast cancer
Do-Youn Oh et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma
Huan Lu et al.
THERANOSTICS (2020)
Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors
Tuan Zea Tan et al.
EUROPEAN UROLOGY (2019)
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
Francois Audenet et al.
CLINICAL CANCER RESEARCH (2019)
Large-scale genomic comparison of UTUC and bladder tumours
Lars Dyrskjot
NATURE REVIEWS UROLOGY (2019)
Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype
Ulrike Zinnall et al.
HUMAN PATHOLOGY (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility
Anissa Moktefi et al.
MODERN PATHOLOGY (2018)
HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)
Francesco Soria et al.
WORLD JOURNAL OF UROLOGY (2017)
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma
Tyler J. Moss et al.
EUROPEAN UROLOGY (2017)
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer
Thomas Powles et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Multicentre randomised phase II trial of gemcitabine plus platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2
Stephane Oudard et al.
EUROPEAN JOURNAL OF CANCER (2015)
HER2 as a target in invasive urothelial carcinoma
Joaquim Bellmunt et al.
CANCER MEDICINE (2015)
Aristolochic acid-associated urothelial cancer in Taiwan
Chung-Hsin Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours
Achim Fleischmann et al.
EUROPEAN UROLOGY (2011)
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
M. Lae et al.
ANNALS OF ONCOLOGY (2010)
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Population-Based Case-Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer Risk
Ming-Nan Lai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas
Vildan Caner et al.
PATHOLOGY & ONCOLOGY RESEARCH (2008)
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma:: Results of a multicenter phase II National Cancer Institute trial
Maha H. A. Hussain et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan
MH Yang et al.
UROLOGY (2002)
Share Paper
